kakiebean
Explorer
I've been working on getting my reta side effects under control. Even on a low dose (2 mg), I get an unpleasant sense of fullness along with some nausea. I had a pretty interesting conversation with my thinking partner (Chat GPT Astra), and I figured some folks here might take something useful away from it. I stripped out the advanced math. Anyone who makes it through the whole thing earns gold stars.
Me: Given the half-life phenomenon and the dosing schedule, will Reta keep building up, or does it level off at some point? Let's say I hold at the 2 mg dose.
Chat:
Yes. It levels off at a steady state. It does not keep building up without limit.
When dosed weekly, the reported half-life of retatrutide is roughly 6 days, which is exactly what makes weekly administration workable from a pharmacokinetic standpoint.
The central idea here is steady-state accumulation:
2−7/6≈0.4452^{-7/6}\approx 0.445
So about 45% of a dose is still there a week later, right when the next injection is due.
That adds up to a meaningful amount of accumulation.
What does that look like?#-what-does-that-look-likeUnder an idealized simple one-compartment model with a 6-day half-life, after repeated weekly dosing:
The amount doesn't just climb 2 mg → 4 mg → 6 mg → 8 mg. It flattens toward a plateau, since every new dose stacks onto a shrinking leftover.
A handy approximation for average steady-state exposure comes from the accumulation factor:
With a 6-day half-life:
R≈1.80R\approx1.80
So under this simplified model, average exposure once you're at steady state is about 1.8 times what a single isolated weekly dose gives you.
And there's a consequence here that matters for what you've been going through.
You're likely already close to steady state at 2 mg#-youre-probably-already-near-steady-state-at-2-mgGetting to steady state happens fairly quickly. Approximately:
So if you've been on 2 mg weekly for several weeks, you won't keep accumulating more and more retatrutide in your body forever. For that dose, you've essentially reached the pharmacokinetic plateau.
This actually matters for how we read your current nausea/fullness. The fact that you're hitting a fairly reproducible ~1,200–1,300 kcal refeed ceiling after multiple 2-mg doses fits with you now feeling the effects of a relatively stable exposure, instead of a drug concentration that keeps rising without end.
Peak/trough swings within each week can still be present. Your bloodstream doesn't hold a flat 2-mg concentration. It goes up after the injection, then falls over the days that follow, with leftover drug from earlier injections forming the baseline beneath it.
For your particular experiment, that's probably the more interesting piece:
steady-state average exposure + a weekly peak/trough pattern
rather than plain “accumulation.”
And the phase 2 trial's dosing scheme is relevant here: participants receiving higher maintenance doses were generally escalated gradually, with dose increases every four weeks, and the investigators specifically found that gastrointestinal adverse events were concentrated during dose escalation and were partially mitigated by starting at 2 mg rather than 4 mg.
So your hunch that “I probably couldn't have started at 2 mg” actually has trial precedent behind it. The gradual exposure you gave yourself was pharmacokinetically meaningful, not merely psychological hand-holding.
Me: Given the half-life phenomenon and the dosing schedule, will Reta keep building up, or does it level off at some point? Let's say I hold at the 2 mg dose.
Chat:
Yes. It levels off at a steady state. It does not keep building up without limit.
When dosed weekly, the reported half-life of retatrutide is roughly 6 days, which is exactly what makes weekly administration workable from a pharmacokinetic standpoint.
The central idea here is steady-state accumulation:
- Every 2-mg injection contributes one more dose.
- At the same time, the earlier doses are steadily being cleared.
- In the beginning, each new dose lands on top of a fairly small leftover amount.
- Over time, the amount still present from earlier injections grows large enough that what gets eliminated in a given week is about equal to what the next 2-mg injection adds.
- Once that happens, average exposure no longer climbs. You've hit steady state.
2−7/6≈0.4452^{-7/6}\approx 0.445
So about 45% of a dose is still there a week later, right when the next injection is due.
That adds up to a meaningful amount of accumulation.
What does that look like?#-what-does-that-look-likeUnder an idealized simple one-compartment model with a 6-day half-life, after repeated weekly dosing:
The amount doesn't just climb 2 mg → 4 mg → 6 mg → 8 mg. It flattens toward a plateau, since every new dose stacks onto a shrinking leftover.
A handy approximation for average steady-state exposure comes from the accumulation factor:
With a 6-day half-life:
R≈1.80R\approx1.80
So under this simplified model, average exposure once you're at steady state is about 1.8 times what a single isolated weekly dose gives you.
And there's a consequence here that matters for what you've been going through.
You're likely already close to steady state at 2 mg#-youre-probably-already-near-steady-state-at-2-mgGetting to steady state happens fairly quickly. Approximately:
- after 1 half-life: 50% of the eventual accumulation
- 2 half-lives: 75%
- 3: 87.5%
- 4: 94%
- 5: 97%
So if you've been on 2 mg weekly for several weeks, you won't keep accumulating more and more retatrutide in your body forever. For that dose, you've essentially reached the pharmacokinetic plateau.
This actually matters for how we read your current nausea/fullness. The fact that you're hitting a fairly reproducible ~1,200–1,300 kcal refeed ceiling after multiple 2-mg doses fits with you now feeling the effects of a relatively stable exposure, instead of a drug concentration that keeps rising without end.
Peak/trough swings within each week can still be present. Your bloodstream doesn't hold a flat 2-mg concentration. It goes up after the injection, then falls over the days that follow, with leftover drug from earlier injections forming the baseline beneath it.
For your particular experiment, that's probably the more interesting piece:
steady-state average exposure + a weekly peak/trough pattern
rather than plain “accumulation.”
And the phase 2 trial's dosing scheme is relevant here: participants receiving higher maintenance doses were generally escalated gradually, with dose increases every four weeks, and the investigators specifically found that gastrointestinal adverse events were concentrated during dose escalation and were partially mitigated by starting at 2 mg rather than 4 mg.
So your hunch that “I probably couldn't have started at 2 mg” actually has trial precedent behind it. The gradual exposure you gave yourself was pharmacokinetically meaningful, not merely psychological hand-holding.
When it comes to conversations like this one, it's genuinely pretty useful.
R for the majority. 
